Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review

Jie Wang; Yigen Shen; Jiaoni Wang; Yangjing Xue; Lianming Liao; Saroj Thapa; Kangting Ji

doi:10.18632/oncotarget.17518

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review

Jie Wang, Yigen Shen, Jiaoni Wang, Yangjing Xue, Lianming Liao, Saroj Thapa and Kangting Ji _

PDF | HTML | How to cite

Oncotarget. 2017; 8:46461-46467. https://doi.org/10.18632/oncotarget.17518

Metrics: PDF 2450 views | HTML 2850 views | ?

Abstract

Jie Wang1,*, Yigen Shen1,*, Jiaoni Wang1, Yangjing Xue1, Lianming Liao2, Saroj Thapa1 and Kangting Ji1

1Department of Cardiology, The Second Affiliated and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325000, Zhejiang, China

2Department of Oncology, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 3250112, Fujian, China

*These authors have contributed equally to this work

Correspondence to:

Kangting Ji, email: [email protected]

Keywords: phosphodiesterase type 5 inhibitors, malignant melanoma, basal cell carcinoma, meta-analysis, systematic review

Received: December 10, 2016 Accepted: April 04, 2017 Published: April 29, 2017

ABSTRACT

Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calculate the summary risk estimates. Five observational studies were included. Five studies reports encompassed a total of 15,979 melanoma cases occurring among 1, 188,414 participants. The pooled multivariable-adjusted RR of melanoma in patients with using PDE5 inhibitors was 1.12 (95% CI: 1.03–1.21, I² = 0.48). Findings from this systematic review support that PDE5 inhibitor use is associated with increased risk of melanoma in ED patients, the result remains inclusive and warrants further study in the future.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17518

Publication Alerts

Post-Publication Promotion

Publication Discount

Meta-Analysis:

Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review

Abstract